Introduction {#s02}
============

In 1931, Lucy Wills reported that an unusual form of anemia, macrocytic anemia, could be cured by yeast extracts, suggesting that the disease is a nutritional deficiency ([@bib22],[@bib23]). Soon thereafter, many groups were racing to identify the active nutrient, later named folic acid or folate. This was at a time when modern chromatography techniques were yet to be developed, yet folic acid was successfully isolated by two independent groups using ingenious methods, including using activated charcoal to adsorb and concentrate folic acid and using a microbiological assay to rapidly detect its activity ([@bib56]; [@bib88]). These intense efforts culminated in 1948, when E.L. Robert Stokstad and colleagues at Lederle Laboratories elucidated the chemical structure of folic acid by chemical degradation and total synthesis ([@bib130]).

Having learned of the discovery of folic acid, Sidney Farber recruited a cohort of leukemic children to test whether folic acid might be able to restore normalcy to the blood cells in leukemia, just as it does in macrocytic anemia ([@bib39]). Although this trial was quickly stopped, as folic acid was found to actually exacerbate the disease, it led to a revised idea that folic acid antagonists might stop leukemia. This revised idea was borne out in Farber's next trial. As described in his landmark paper in 1948 ([@bib38]), one of the tested folic acid antagonists, aminopterin, produced temporary remission in children with acute lymphoblastic leukemia. Thus, the era of cancer chemotherapy had begun.

What also ensued was a "golden era" for enzymology in general (1950--1960; [@bib54]), during which many enzymes involved in folate metabolism were purified from crude cell or tissue extracts and characterized, and their reactions merged into coherent pathways. Among these enzymes, dihydrofolate reductase (DHFR) was identified as the major target of aminopterin and its more widely used close analogue, methotrexate ([@bib153]; [@bib53]). In the following decades, rapid development of molecular biology techniques allowed cloning of the genes encoding the enzymes, and Robert Schimke discovered that amplification of the *DHFR* gene confers tumor resistance to methotrexate. Remarkably, this was the first known case of gene amplification in mammalian somatic cells ([@bib116]).

Many excellent reviews on folate metabolism have appeared over the past decade, some of which cover metabolic compartmentation ([@bib139]; [@bib118]), folate transport ([@bib161]), and the roles of folates in redox homeostasis ([@bib34]), embryonic development ([@bib89]), cancers ([@bib71]; [@bib156]), and plants ([@bib49]).

It is sometimes claimed in the current literature that all the components in the metabolic pathways have been identified, and the challenge now is to understand how the metabolic fluxes are regulated. While we wholeheartedly agree with the latter point, we share with others the opinion that many components in mammalian folate metabolism remain to be identified, and their functions remain to be understood. Recently introduced disciplines, such as comparative genomics ([@bib43]), functional genomics ([@bib151]; [@bib122]; [@bib52]), and organelle proteomics ([@bib25]; [@bib101]; [@bib20]), have opened up new opportunities for solving these remaining puzzles. Thus, in this review, we emphasize missing links and underdeveloped areas and discuss potential approaches to illuminate them. We begin with a survey of folate chemistry, an important aspect of folate metabolism that is sometimes overlooked.

Structure and chemistry of folates {#s03}
==================================

Nomenclature {#s04}
------------

By convention, "folates" is a generic term, referring to a large family of compounds consisting of a 2-amino-4-hydroxy-pteridine ring, linked by a methylene (CH~2~) group to a *p*-aminobenzoyl moiety, which is in turn linked through amide bond to the α-amino group of a monoglutamate or poly-γ-glutamate ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib12]). One-carbon (1C) units can be attached to N5, N10, or both. On the other hand, the name "folic acid" is reserved for the synthetic form with the fully oxidized pteridine ring and no 1C substitution ([Fig. 1 B](#fig1){ref-type="fig"}).

![**Folate chemistry. (A)** Chemical structure of THF. **(B)** Redox reactions for the pteridine ring of folates. **(C)** The 1C unit is derived from donors such as serine, exists in three different oxidation states, and is used for various biochemical processes.](JEM_20181965_Fig1){#fig1}

The number of distinct molecular species within the folate family could be as many as 150, due to the combinatorial effect of varying 1C and pteridine oxidation states and varying polyglutamate chain lengths ([@bib62]). Nevertheless, typically \<50 species are detectable in natural animal and plant sources ([@bib47]), with the pteridine ring predominantly in the most reduced, tetrahydro state ([Fig. 1 B](#fig1){ref-type="fig"}), N5 and N10 either unsubstituted or substituted with one of six different 1C units ([Fig. 1 C](#fig1){ref-type="fig"}), and the polyglutamate chain length being predominantly five to eight ([@bib69]).

Folates as 1C carriers or electron carriers {#s05}
-------------------------------------------

In most folate-mediated reactions, tetrahydrofolate (THF) serves as a 1C carrier, which obtains the 1C unit from a donor (e.g., serine) and then transfers it to an acceptor, typically a biosynthetic intermediate. The attached 1C units exist in three different oxidation states that are equivalent to methanol, formaldehyde, and formate ([Fig. 1 C](#fig1){ref-type="fig"}) and can be interconverted by cellular enzymes using nicotinamide adenine dinucleotide phosphate (NADP) or nicotinamide adenine dinucleotide (NAD) as a cosubstrate.

Although the pteridine ring in folates is capable of undergoing redox reactions, this capability is rarely used. A notable exception occurs in the thymidylate synthase--catalyzed reaction ([Fig. 1 B](#fig1){ref-type="fig"}), in which the folate pteridine ring undergoes a two-electron oxidation. To sustain THF levels, therefore, DHFR is required to act downstream of thymidylate synthase to recycle DHF back to THF.

Chemical lability of reduced folates {#s06}
------------------------------------

Naturally occurring, reduced folates are chemically labile. In fact, the first identified folate, folic acid, was likely an artifact due to the lengthy isolation procedures, during which natural folates were largely decomposed by reacting with molecular oxygen, and a minor component among the oxidized products was folic acid ([@bib62]). The chemical lability is an important aspect of folates, not only presenting a technical challenge for their chemical analysis, but also reflecting their tendency to break down in vivo. Antioxidants, ascorbate in particular, are effective in minimizing folate decomposition and have proved useful in various analytical methods for folates ([@bib112]).

Different classes of folates, defined by the pteridine oxidation state and the 1C identity, display markedly different stabilities and follow distinct degradation pathways. We describe the pathways for each class, roughly in the order of increased stability.

### THF {#s07}

In the absence of antioxidants, the half-life of THF in aqueous solutions at 37°C is typically \<30 min ([@bib108]). The pathway of THF decomposition is mediated by quinoid DHF (qDHF), generated via a free radical mechanism ([Fig. 2 A](#fig2){ref-type="fig"}). qDHF is unstable and readily cleaves into 7,8-dihydropterin, formaldehyde, and *p*-aminobenzoylglutamate (pABG; [@bib114]; [@bib19]). Formaldehyde is a potent cross-linker for proteins and nucleic acids ([@bib19]).

![**Folate decomposition and damage repair. (A)** Chemical pathway of THF decomposition. **(B)** Cellular enzymatic systems for folate damage repair.](JEM_20181965_Fig2){#fig2}

### 10-Formyl-THF {#s08}

In the absence of antioxidants, 10-formyl-THF is readily oxidized to 10-formyl-DHF (half-life, typically \<30 min at 37°C), and on prolonged incubation, is further oxidized to 10-formyl-folic acid ([@bib5]; [@bib4]).

### 5,10-CH~2~-THF and 5,10-CH^+^-THF {#s09}

There appear to be few reports on the stability of 5,10-CH~2~-THF and 5,10-CH^+^-THF, presumably because 5,10-CH~2~-THF is in equilibrium with THF and formaldehyde ([@bib59]), and 5,10-CH^+^-THF would hydrolyze to 10-formyl-THF and, to a much lesser degree, 5-formyl-THF at neutral pHs ([@bib132]).

### DHF {#s10}

DHF is much more stable than THF, with a half-life of 4.5 h at 30°C, pH 7.0 ([@bib114]). DHF can undergo either pteridine ring oxidation to folic acid or C9-N10 cleavage to pABG and 6-formyl-dihydropterin or dihydroxanthopterin ([@bib27]; [@bib114]). The partition into these three pathways seems to depend on the pH and the type of buffer ([@bib27]; [@bib114]).

### 5-Methyl-THF {#s11}

5-Methyl-THF can be readily oxidized to 5-methyl-5,6-DHF. In the presence of thiols or ascorbate, 5-methyl-5,6-DHF readily reverts to 5-methyl-THF. Conversely, when subject to more oxidative conditions, 5-methyl-5,6-DHF either rearranges to a 5-methyl-dihydro-pyrazino-s-trazine compound or cleaves into an unidentified pterin and pABG ([@bib47]).

### Folic acid and 5-formyl-THF {#s12}

These two species are stable to oxidation, except under harsh conditions such as in the presence of KMnO~4~ ([@bib78]).

Paradoxical stability of folates in vivo {#s13}
----------------------------------------

Given the intrinsic tendency of reduced folates to decompose, it is surprising that folates were found to be extremely slowly turned over in human whole body or in cultured mammalian cells ([@bib61]; [@bib146]; [@bib64]). For example, using a ^2^H-folic acid tracer, folate breakdown rates in adult humans were estimated to be ∼0.5% per day (half-life, ∼19 d; [@bib146]). This is in stark contrast to the situation in plants, where folate breakdown is very rapid, at a rate of ∼10% per day ([@bib98]).

A series of excellent reviews ([@bib70]; [@bib66]; [@bib134]) emphasized two important facets of metabolism that were largely overlooked in classic textbooks of biochemistry. First, enzymes are not always exquisitely specific and efficient, and many of them also catalyze unwanted side reactions. Moreover, many metabolites are chemically labile and reactive, and thus prone to damage. To counter such metabolite damage, cells have often evolved dedicated metabolite repair enzymes. In an example related to folate metabolism, 5-formyl-THF, a dead-end metabolite formed from 5,10-CH^+^-THF by a side reaction of serine hydroxymethyltransferases (SHMT1/2; [@bib131]) or spontaneously at mildly acidic pHs ([@bib4]), is salvaged by methenyl-THF synthetase (MTHFS) back to 5,10-CH^+^-THF in eukaryotes and most prokaryotes ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib70]).

We recently found that cellular THF decomposition can be prevented by an enzyme, quinoid dihydropteridine reductase (QDPR); specifically, the qDHF intermediate of THF decomposition can be reduced by QDPR back to THF at the expense of two reducing equivalents from NADH ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib162]). Moreover, the oxidation product of 10-formyl-THF, 10-formyl-DHF, can be reduced back to 10-formyl-THF by DHFR, or to THF by tandem actions of ATIC and DHFR ([Fig. 2 B](#fig2){ref-type="fig"}; [@bib162]). Thus, the oxidative damage to the two least stable folates, THF and 10-formyl-THF, can be enzymatically repaired in mammalian cells.

It is likely that other factors also contribute to folate stability in vivo. For example, folates can be stabilized through protein binding ([@bib155]; [@bib30]; [@bib85]; [@bib58]). In addition, the reduced intracellular milieu maintained by glutathione- and thioredoxin-mediated systems may play an indispensable role as well.

Folate pathways: Identified and unidentified components {#s14}
=======================================================

Among the three processes we discuss in this section, folate uptake and catabolism typically occur on a much slower timescale than most 1C transfer reactions, consistent with the cell's differential needs for folate and 1C. Folate is needed only in catalytic amounts to function as a cofactor, whereas 1C must be rapidly transferred via heavy-traffic pathways to support demanding processes such as nucleotide synthesis.

Folate uptake and intracellular accumulation {#s15}
--------------------------------------------

### Folate uptake at the cell surface {#s16}

At the plasma membrane, two transmembrane carriers (SLC19A1 and SLC46A1) and three glycosylphosphatidylinositol-anchored receptors (FOLR1--3) can mediate folate uptake ([Fig. 3 A](#fig3){ref-type="fig"}; [@bib161]). The substrate of these transporters and receptors is folate monoglutamate, consistent with the fact that the circulating folate is predominantly 5-methyl-THF monoglutamate ([@bib113]). SLC19A1, also known as the reduced folate carrier, is a widely expressed antiporter that exchanges a reduced folate for another anion substrate. Candidates for the counter substrate of SLC19A1, including thiamine phosphates and 5-aminoimidazole-4-carboxamide ribonucleotide monophosphate (ZMP or AICAR), have been suggested ([@bib145]). ZMP is an intermediate in purine biosynthesis and is known to accumulate in folate deficiency, in both bacteria ([@bib129]; [@bib14]) and mammal cells ([@bib50]; [@bib83]). Therefore, using ZMP as a counter substrate for SLC19A1 would represent an elegant feedback mechanism for regulating intracellular folate homeostasis.

![**Folate transport and metabolic compartmentation. (A)** Knowledge gaps in cellular folate metabolism. **(B)** Parallel cytosolic and mitochondrial folate pathways.](JEM_20181965_Fig3){#fig3}

SLC46A1, also known as the proton-coupled folate transporter, is most active at acidic extracellular pHs. Consistent with its low pH optimum, SLC46A1 catalyzes symport of protons with the folate substrate, notably in the acidic, upper region of the small intestine, where it is highly expressed. Loss-of-function mutations in SLC46A1 are the only known cause of the rare disease hereditary folate malabsorption ([@bib111]; [@bib159]).

The folate receptors, strongly expressed in certain epithelial tissues and some gynecological cancers, mediate folate uptake through an endocytic pathway, but the exact mechanism is a matter of debate ([@bib103]; [@bib24]). Whatever the mechanism, to support cellular folate-dependent functions, the internalized folate monoglutamate must be effluxed from an internal vesicular compartment into the cytosol ([Fig. 3 A](#fig3){ref-type="fig"}). It has been suggested that SLC46A1 could mediate this efflux ([@bib160]), yet the same authors also pointed out that FOLR1 can function normally in some cells that lack SLC46A1 expression, indicating that there is at least one alternative transporter ([@bib161]).

### Folate uptake into the mitochondria {#s17}

At the mitochondrial inner membrane, SLC25A32, a member of the mitochondrial carrier family that consists of ∼50 proteins, imports reduced folate monoglutamates into the mitochondrial matrix ([Fig. 3 A](#fig3){ref-type="fig"}). Surprisingly, however, human *SLC25A32* cDNA was able to complement the growth defects of a yeast mutant lacking a homologous gene, *FLX1*, that encodes a putative mitochondrial flavin adenine dinucleotide (FAD) transporter ([@bib128]). Recently, compound heterozygous mutations in *SLC25A32* were found in a patient with riboflavin-responsive exercise intolerance, further supporting a link between SLC25A32 and FAD metabolism ([@bib115]). Thus, these studies have raised the question of whether mammalian SLC25A32 is a carrier for folate, FAD, or both.

The virtual absence of mitochondrial folates in *SLC25A32* mutant Chinese hamster ovary (CHO) cells strongly argues that folate is a bona fide substrate for SLC25A32 ([@bib140]; [@bib82]). In contrast, FLX1-deficient yeast still has sizable mitochondrial FAD ([@bib142]). Moreover, mammalian mitochondria ([@bib7]; [@bib20]), and possibly yeast mitochondria as well ([@bib3]), can synthesize FAD from riboflavin using riboflavin kinase and FAD synthetase, so it is not apparent why FAD needs to be imported from the cytosol. Given that the transport mechanism of SLC25A32 remains to be further delineated ([@bib63]), it is possible that SLC25A32 is an antiporter that couples folate import with FAD export ([Fig. 3 A](#fig3){ref-type="fig"}). Consistent with this possibility, yeast FLX1 has been suggested to be a mitochondrial FAD export carrier ([@bib3]).

### Cytosolic and mitochondrial folate retention by polyglutamation {#s18}

Folate polyglutamation, catalyzed by folylpolyglutamate synthetase (FPGS), plays an indispensable role for intracellular folate accumulation. In cells lacking FPGS, folate monoglutamates that have been taken up will readily efflux out of the cell, resulting in only ∼10% of normal folate accumulation ([@bib99]). Thus, polyglutamation adds multiple negative charges to the imported folates and thereby dramatically enhances their intracellular accumulation. Moreover, polyglutamation markedly increases the affinity of most folate-dependent enzymes for their folate substrate ([@bib80]).

DHF, THF, and 10-formyl-THF are efficient substrates for FPGS, whereas 5-methyl-THF, 5-formyl-THF, and folic acid are poor substrates ([@bib29]). Because 5-methyl-THF is the major circulating folate, its conversion by methionine synthase (MTR) to THF is thought to be the first metabolic step in cells that precedes polyglutamation ([@bib31]).

FPGS is expressed in most tissues as at least two isoforms that result from alternative splicing and alternative translational start sites, one of which targets to the mitochondrial matrix ([@bib64]). This enables the establishment of distinct, nonmiscible cytosolic and mitochondrial folate pools that operate in two parallel pathways, described next.

Parallel cytosolic and mitochondrial 1C pathways {#s19}
------------------------------------------------

Parallel 1C pathways exist in the cytosol and in mitochondria, respectively, each composed of a core set of serine hydroxymethyltransferase, CH~2~-THF dehydrogenase/CH^+^-THF cyclohydrolase, and 10-formyl-THF synthetase activities ([Fig. 3 B](#fig3){ref-type="fig"}; [@bib125]). These two pathways are connected by small metabolites that can readily traverse the mitochondrial inner membrane, such as serine, glycine, and formate. The consensus for the interrelationship of the two pathways is that the mitochondrial 1C pathway produces formate, which in turn is used in the cytosolic pathway for purine, dTMP, and methionine biosynthesis, or excreted out of the cell if in excess ([@bib28]; [@bib139]; [@bib84]; [@bib34]).

Recently, SFXN1 has been identified as a mitochondrial serine transporter ([@bib60]). SLC25A38 has been suggested to be a mitochondrial glycine transporter ([@bib40]; [@bib73]). However, the genes encoding mitochondrial transporters for formate, sarcosine, and dimethylglycine remain unknown ([Fig. 3 A](#fig3){ref-type="fig"}).

Another well-recognized role for the mitochondrial 1C pathway is glycine synthesis ([@bib140]; [@bib28]; [@bib139]; [@bib57]; [@bib34]). A long-standing question is why the cytosolic SHMT1 cannot produce sufficient glycine. To generate glycine continuously via SHMT1, THF has to be continuously regenerated. For the cytosolic 1C pathway operating in the direction of glycine synthesis, THF regeneration is impeded by the unfavorable NADP/NADPH and ADP/ATP ratios in the cytosol ([@bib144]; [@bib28]). Our recent work showed that overexpression of *ALDH1L1* can overcome this thermodynamic barrier by bypassing the unfavorable 10-formyl-THF synthetase step, thereby allowing continuous THF regeneration and glycine synthesis in the cytosol ([@bib162]).

The mitochondrial 1C pathway also supports mitochondrion-specific functions. It is well known that mitochondrial 10-formyl-THF is used for N-formylation of the initiator methionine in mitochondrial methionyl-tRNA^Met^. Loss-of-function mutations in the human formyltransferase gene, *MTFMT*, have been causally linked to Leigh syndrome, a mitochondrial disease ([@bib141]). Unexpectedly, a recent study showed that *SHMT2*-knockout HCT116 cells contained normal levels of formylmethionine in mitochondrially translated peptides ([@bib91]). In contrast, another recent study found severe depletion of mitochondrial formyl-methionyl-tRNA^Met^ in *SHMT2*-knockout Jurkat cells ([@bib87]). It remains to be clarified whether these discrepancies can be accounted for by the differences in the cell line context, and if so, what the context-specific modulators are.

Recent research is also beginning to reveal a surprising role for mitochondrial 5,10-CH~2~-THF in mitochondrial protein translation. These studies, first performed on prokaryotic systems, highlight the synergy between genetic, structural, and biochemical approaches. It was first established, through genetics, that two bacterial proteins, MnmE and MnmG, are involved in modifying uridine at the wobble position of certain bacterial transfer RNAs (tRNAs) to 5-methyluridine derivatives ([@bib37]; [@bib48]), yet the biochemical understanding was lagging behind.

A breakthrough came when x-ray crystallography revealed that MnmE contains a folate-binding fold strikingly resembling that in several known folate-binding enzymes ([@bib119]; [@bib120]). This revelation enabled the long-awaited in vitro reconstitution experiments, in which various THF derivatives were tested (together with other known cosubstrates) for the ability to stimulate the reaction of the MnmE/MnmG complex with tRNAs ([@bib92]; [@bib2]). Indeed, 5,10-CH~2~-THF was found to be active and was suggested to be an essential cofactor for MnmE/MnmG.

The human orthologues of MnmE and MnmG, GTPBP3 and MTO1, have been predicted to be responsible for the occurrence of 5-taurinomethyluridine at the wobble position in certain mitochondrial tRNAs ([@bib136]; [@bib135]). To date, successful in vitro reconstitution for this putative activity has not been published. However, compelling genetic evidence has been provided by a recent study: knocking out either *MTO1* or *SHMT2* (which supplies mitochondrial 5,10-CH~2~-THF) in HCT116 cells resulted in no detectable levels of 5-taurinomethyluridine in mitochondrial tRNAs ([@bib91]). Consistent with the crucial role of this wobble uridine modification in stabilizing codon--anticodon pairing, these knockout cells were defective in mitochondrial protein translation ([@bib91]). Thus, the mitochondrial folate pathway provides the 5,10-CH~2~-THF substrate for GTPBP3/MTO1-mediated mitochondrial tRNA modification in human cells, an important finding with relevance to the mitochondrial disorders myoclonic epilepsy with ragged red fibers and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, which are caused by defective 5-taurinomethyluridine modification ([@bib136]; [@bib135]).

Our understanding of mitochondrial folate metabolism is not yet complete, however. Like MnmE, another bacterial protein YgfZ contains a folate-binding fold in its crystal structure, and its folate-binding activity was confirmed by biophysical experiments ([@bib138]). *YgfZ* homologues (named *IBA57* for the human gene) occur in all domains of life and, through a poorly understood mechanism, are essential for the assembly or maintenance of certain iron-sulfur proteins in bacteria ([@bib149], [@bib150]) and in yeast ([@bib46]) and human ([@bib124]) mitochondria ([Fig. 3 A](#fig3){ref-type="fig"}). At least in bacteria, the function of YgfZ in iron-sulfur cluster metabolism is folate dependent ([@bib149], [@bib150]). Further investigation into IBA57 is much needed to fully decipher the mitochondrial respiration defects caused by impaired mitochondrial folate metabolism.

Folate catabolism {#s20}
-----------------

Folate catabolism is extremely slow under normal conditions, but can be greatly accelerated with methotrexate treatment ([@bib162]). The bulk of folate catabolism in vivo is accounted for by the appearance of *p*-acetamidobenzoylglutamate (pAcABG) and pterins, products of folate C9-N10 bond cleavage, in urine ([@bib94]; [@bib61]). Whereas the C9-N10 bond cleavage is probably spontaneous, reflecting folate intrinsic instability, formation of pAcABG from the direct cleavage product pABG requires an enzyme, the NAT1 acetyltransferase ([@bib86]; [@bib148]).

The cellular pathways for folate catabolism are poorly understood. Because plasma membrane efflux is prohibited for polyglutamated folates, pABG, or pAcABG, conversion of folate polyglutamate into folate monoglutamate, or deglutamation, is required for cellular clearance of folate catabolites. The only known enzyme capable of folate deglutamation is γ-glutamyl-hydrolase (GGH), which is either contained within lysosomes or secreted into the extracellular space ([@bib55]). Consistent with the role of GGH in folate deglutamation, GGH up-regulation was associated with a shift in intracellular folate distribution to shorter polyglutamate species in a hepatoma cell line ([@bib157]). To access GGH, polyglutamated folates, pABG, or pAcABG have to be imported into the lysosome. A lysosomal carrier specific for polyglutamated rather than monoglutamated methotrexate was reported in the 1990s ([@bib8]; [@bib127]), but many questions remain unanswered, such as its gene identity and whether it preferentially imports cleaved folates ([Fig. 3 A](#fig3){ref-type="fig"}). The acidic pH (∼4.5) of lysosomal lumen is expected to precipitate some spontaneous reactions of folates, such as the conversion of 5,10-CH^+^-THF to 5-formyl-THF ([@bib4]). Finally, it remains to be determined whether the monoglutamate product of GGH is directly secreted via lysosomal exocytosis ([@bib121]) or first released into the cytosol via a lysosomal carrier.

Approaches to identify missing components {#s21}
-----------------------------------------

Historically, many components involved in folate metabolism were discovered by biochemical purification to chase down the protein responsible for an activity of interest ([@bib137]; [@bib54]) and by forward genetic screens followed by cDNA complementation ([@bib33]; [@bib140]). The use of radioactive folic acid tracer in rats also greatly accelerated the discoveries of folate transporters/receptors and folate-binding enzymes for which folate was not an expected substrate but later proved to be an integral component of their catalysis ([@bib147]; [@bib44]). More recently, searching for paralogs in the then just-completed human genome database allowed identification of missing genes for known activities ([@bib110]; [@bib15]).

It is possible that saturation has not been reached in traditional forward genetic screens where chemical-induced mutagenesis could have target bias. Moreover, in some cases, the causal gene remains elusive. For example, glycine auxotrophic mutants of CHO cells discovered in the 1970s ([@bib26]; [@bib81]) fall into four complementation groups: *GLYA* (=*SHMT2*), *GLYB* (=*SLC25A32*), *AUXB1* (=*FPGS*), and *GLYC*/*AUXB2*. Although the growth defect of the *GLYC* mutant was complemented by human *DHFR2* (also named *DHFRL1*) cDNA ([@bib1]), the *DHFR2* gene does not exist in the rodent from which the CHO line was derived. Thus, the *GLYC*/*AUXB2* gene remains to be identified, for example by RNA or whole-exome sequencing.

The radioactive folic acid tracer approach had been limited to folate binders that are highly abundant and show high affinity (dissociation constant = submicromolar or lower) toward its folate ligand ([@bib85]). The same limitations would be encountered if a folate affinity column ([@bib154]) were used to pull down potential binders ([@bib18]). Although protein abundance is less an issue with the advent of highly sensitive mass spectrometry instruments, the requirement for tight binding remains a hurdle. Thus, new proteomic approaches such as thermal proteome profiling ([@bib77]; [@bib42]) and limited proteolysis--small molecule mapping ([@bib105]), developed to capture both strong and weak protein--ligand interactions in cells, can be powerfully complementary.

If an activity is known to localize to an intracellular organelle (e.g., lysosomes or mitochondria), then the search for the gene can be dramatically narrowed down to dozens or fewer candidates by referring to published inventories of genes encoding proteins for that organelle ([@bib25]; [@bib101]; [@bib20]). A caveat is that these inventories have incomplete coverage and finite false discovery rates ([@bib101]), and moreover, for the lysosome, it might be difficult to distinguish resident proteins from cargo proteins delivered there for degradation ([@bib25]). Nevertheless, recent success stories, such as the discoveries of the mitochondrial pyruvate carrier ([@bib17]; [@bib51]) and the mitochondrial calcium uniporter ([@bib9]), highlight the excellent potential for this approach.

The above organelle proteomics--based approach correlates an activity with a list of proteins on the basis of subcellular colocalization. Yet there are other ways to infer correlations. For example, genes with unknown functions can be linked to genes with well-defined functions on the basis of coevolution, coexpression, protein--protein interactions, suppression and synthetic interactions, and for microbial orthologues of a candidate human gene, gene clustering and gene fusion (<https://string-db.org/> and <https://thebiogrid.org/>; [@bib101]; [@bib96]). To further understand the function of a gene of interest, one may zero in on short stretches of protein-encoding or promoter sequences and correlate the protein or DNA sequences with well-defined protein kinase phosphorylation or transcription factor binding motifs, as detailed in previous reviews ([@bib41]; [@bib76]) and exemplified by some recent studies ([@bib10], [@bib11]; [@bib158]; [@bib32]; [@bib65]). Ultimately, the hypotheses thus generated need to be tested using genetic, biochemical, and pharmacological approaches.

Interaction of the folate cycle with the methionine cycle {#s22}
=========================================================

ATP, NAD, and NADP are universal cofactors in metabolism. Therefore, folate pathways are connected to almost every other metabolic pathway through shared ATP, NAD, and NADP pools. Although folate pathways can contribute to the production of NADPH and ATP, their fluxes are also directly affected by compartment-specific ATP/ADP, NAD/NADH, and NADPH/NADP ratios. Recently it has been proposed that NADPH produced by ALDH1L2 in the mitochondrial 1C pathway is important to limit mitochondrial ROS ([@bib107]; [@bib156]). Here, we further discuss the methionine cycle, which is linked to folate cycle via a more "specialized" metabolite, 5-methyl-THF ([Fig. 4](#fig4){ref-type="fig"}).

![**The folate cycle is linked to the methionine cycle via MTHFR and vitamin B12--using MTR.**](JEM_20181965_Fig4){#fig4}

The link between folate and methionine cycles has long been recognized, since a deficiency in either folate or vitamin B12 (an essential cofactor for MTR) produces megaloblastic anemias that are hematologically indistinguishable ([@bib123]). The megaloblastic anemia in both cases is ascribed to defective DNA synthesis and can be reversed by large doses of folates. Thus, vitamin B12 deficiency causes functional folate deficiency, and this is best explained by the methyl trap model ([@bib123]). Methylenetetrahydrofolate reductase (MTHFR)--catalyzed conversion of 5,10-CH~2~-THF to 5-methyl-THF is irreversible in cells, due to the large negative standard free-energy change and high cytosolic NADPH/NADP ratios ([@bib79]). In addition, methionine synthase is the only enzyme that can remove the methyl group from 5-methyl-THF. Thus, a lack of vitamin B12 and thus MTR activity would irreversibly trap folates into 5-methyl-THF, at the expense of 5,10-CH~2~-THF and 10-formyl-THF, both of which are crucial to DNA synthesis.

The original methyl trap model has been expanded to include two subsequent developments. First, MTHFR is allosterically inhibited by S-adenosyl-methionine (SAM) with an inhibition constant of 2.8 µM ([@bib123]). Thus, large doses of methionine can increase intracellular SAM, block the methyl trap, and thereby ameliorate both folate and B12-deficient megaloblastic anemia. Second, as discussed above, the MTR-catalyzed conversion of 5-methyl-THF to THF is likely the first folate metabolic step in cells that precedes polyglutamation, so vitamin B12 deficiency would also compromise intracellular folate polyglutamation and retention. This explains the clinically observed, diminished total cellular folate content in vitamin B12 deficiency.

It is currently unresolved to what extent the folate cycle contributes to cellular methylations in normal physiology and diseases such as cancers. *MTHFR*-knockout mice are viable, and some clinical symptoms of human MTHFR deficiency may be ascribed to hyperhomocysteinemia rather than alterations in methylation ([@bib117]). Many cultured cell lines are unable to proliferate when the medium methionine is replaced with homocysteine ([@bib16]; [@bib68]), and indeed stable isotope labeling and mass spectrometry analysis indicated that for many cell lines, the contribution of serine and folate pathways to the active methyl group is insignificant compared with medium methionine ([@bib106]; [@bib126]; [@bib35]; [@bib74]). Understanding the mechanistic bases for such methionine dependency in cancer cell lines should be an important future direction, especially in light of the recent discoveries that many oncogenic mutations directly impact DNA and histone methyltransferases and demethylases ([@bib45]).

Functions of folate metabolism and disease connections {#s23}
======================================================

The biochemical outputs of folate metabolism include nucleotide synthesis, serine-glycine interconversion, mitochondrial tRNA modification, and methyl group biogenesis, which in turn supports cellular functions such as proliferation, mitochondrial respiration, and epigenetic regulation. Abnormal folate metabolism has been causally linked with a myriad of diseases. However, for each disease, it is often unclear which biochemical processes and cellular functions are culprits.

The earliest known folate-related disease is probably megaloblastic anemia. Systemic folate deficiency, whether dietary, alcohol or drug induced, or due to germline mutations in *DHFR* or *SLC46A1* ([@bib111]; [@bib6]; [@bib21]), invariably results in megaloblastic anemia. The molecular basis for megaloblastic anemia has been ascribed to deranged DNA synthesis, which results in chromosome breakage, and continued cell growth without division during red blood cell production ([@bib123]). In some other cell types, folate deficiency can cause uracil misincorporation into DNA, leading to chromosome breakage ([@bib13]). It has been proposed that such breaks could contribute to the increased risk of cancer ([@bib13]).

Cerebral folate deficiency, caused by folate receptor autoantibodies or germline mutations in *FOLR1* or *SLC46A1*, is manifested in neurological impairments and shows some resemblance to severe MTHFR deficiency ([@bib152]). Thus, folate metabolism plays a crucial, yet poorly defined, role in the brain.

Insufficient folate intake around and during pregnancy has been associated with increased risk of neural tube defects, which is the basis for the mandatory folate fortification of foods in the US since 1998 ([@bib89]). Strong evidence for the role of the mitochondrial folate pathway in neural tube development has been provided by a *MTHFD1L*-knockout mouse model, which presents neural tube defects with 100% penetrance while on a folate-proficient diet ([@bib90]). In addition, mice deficient in the *AMT* or *GLDC* gene, encoding a subunit of the glycine cleavage system, also developed neural tube defects with partial penetrance ([@bib95]; [@bib102]). It was further shown with the *MTHFD1L* or *GLDC-*knockout mice that supplementation with formate rescued the neural tube defects ([@bib90]; [@bib102]). In a recent study, further deletion of *MTHFR* in *GLDC*-null mouse embryos resulted in significant protection from neural tube defects, suggesting that folate and formate-supported nucleotide synthesis, rather than MTHFR-mediated methyl group biogenesis, is crucial for neural tube development ([@bib67]).

Conversely, excess folate intake may enhance proliferation of malignant tumors ([@bib133]). Moreover, genes encoding enzymes in serine biosynthesis and the mitochondrial folate pathway are often amplified or overexpressed in cancers ([@bib72]; [@bib109]; [@bib97]). It has been suggested that metabolic activities under oncogenic control in cancers can be categorized based on whether they are transforming, enabling, or neutral ([@bib143]). As attested by the successes of methotrexate and other antifolates in treating cancers, it is likely that serine biosynthesis and mitochondrial folate metabolism belong to the first two categories, and therefore are potential therapeutic targets ([@bib93]; [@bib100]; [@bib36]). On the other hand, restriction of dietary serine and glycine has been proposed to treat cancers that lack up-regulation of de novo serine biosynthesis ([@bib75]).

Future perspectives {#s24}
===================

Throughout this review, we have highlighted areas that await further development and discussed how to explore them using existing technologies. Yet it is hard to predict where upcoming technologies will lead us. From a biochemical perspective, we envision a future where the entire human proteome is structurally solved ([@bib104]) and the folate binding fold ([@bib120]) might be revealed in many more proteins, thus pushing forward a new level of understanding of folate metabolism in human health and disease.
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